Aurinia Pharmaceuticals Inc (AUPH)

Aurinia Pharmaceuticals Inc (AUPH) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $2.2B; returns 1 day -2.7%, 1 week +2.1%, 1 year +45.6%.

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company focused on autoimmune diseases, primarily driven by its flagship product, LUPKYNIS (voclosporin). LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN) and accounts for over 95% of the company's total revenue, which is projected to reach approximately $275M–$280M for fiscal year 2025.

Groups AUPH belongs to

• Shrinking Share Count
• Biotechnology
• Buying Back Stock
• Canada Companies
• Autoimmune Diseases
• Pharmaceuticals
• Biopharmaceutical
• Commercial Stage Biotech
• Healthcare
• Commercial Stage
• Life Sciences

AUPH financial model: income statement, cash flow and balance sheet